Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)

Hematological Oncology - United Kingdom
doi 10.1002/hon.96_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin

JAAD Case Reports
Dermatology
2019English

Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Primary Cutaneous CD30-positive Large T-Cell Lymphoma With Secondary Lymph Node Involvement Detected by Sentinel Lymphonodectomy

Acta Dermato-Venereologica
DermatologyMedicine
2002English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression

Blood
BiochemistryImmunologyCell BiologyHematology
1999English

Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma. A Series of Nine Cases

Gaceta Medica de Mexico
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy